Source: GlobeNewswire

Press Release: Entasis : Entasis Therapeutics to Participate in the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit

WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will host one-on-one meetings with investors at the 5th Annual SunTrust Robinson Humphrey (STRH) Annual Life Sciences Summit being held May 7-9, 2019 in New York, New York.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Manos Perros's photo - President & CEO of Entasis Therapeutics Holdings, Inc.

President & CEO

Manos Perros

CEO Approval Rating

89/100

Entasis is a biotechnology company that develops and commercializes antibiotic therapies for the treatment of bacterial infections. Read more